BrightOwl Loader Loading


- 27 years oncology Drug Development experience in pharma. - worked for both large & small pharmas; biotech & cros. - 6 years international experience based in brussels (bms). - global team Leadership in a highly matrixed environment. my personal goal: 1 in 3 of us will face Cancer during our lives. we desperately need new treatments for all types of cancers. my goal is to help develop new Cancer treatments to meet the unmet needs of Cancer patients worldwide. i have had the great opportunity to lead the late stage clinical study for votrient (pazopanib) in advanced soft tissue sarcoma. specialties: worked across all phases of oncology Drug Development. development experience includes taxanes, Monoclonal Antibodies, novel biologics; Monoclonal Antibodies and cytoprotective agents. managed global Clinical trials in lung, breast; genitourinary; gastro-intestinal and solid tumours (with experience from first in man to registration and into Phase IV). active Member of asco and esmo. broad experience in developing clinical Strategy and plans for novel therapeutics.


Current Experience

  • Director - Clinical Development Oncology - Global Medical Affairs

    Since March 2015
    i have become part of novartis oncology following the completion of the recent purchase of gsk oncology by novartis. i continue to support votrient (pazopanib) for both rcc & sts indications I have become part of Novartis Oncology following the completion of the recent purchase of GSK Oncology by Novartis. I continue to support Votrient (Pazopanib) for both RCC & STS indications

Past Experience

  • Director - Oncology Global Medical Affairs

    January 2012 --- March 2015
    Member of the votrient global medical team supporting global medical activities for the soft tissue sarcoma indication. i also support votrient medical teams for asia pac / emerging markets / japan.

  • Director / Clinical Leader

    September 2006 --- January 2012
    votrient™ (pazopanib) Clinical indication Leader for sarcoma and Clinical lead for the Phase III (palette) study team. the successful Phase III study was recently published in the lancet - throughout 2009 i worked for oncology R&D in the apjem (asia pacific - japan - emerging markets) team, and returned to palette team in 2010.

  • Director/Clinical Leader - Oncology

    May 2001 --- September 2006
    Clinical Leader for 2 of pfizer's oncology development programmes.

  • Associate Director - International Clinical Research

    December 1999 --- May 2001
    managed global studies (ex-us) for agouron in oncology & hiv. head of agouron's uk Clinical operation

  • Senior Clinical Manager - Oncology & Biotherapeutics

    January 1997 --- January 1999
    contract Research house: managed oncology development programmes on behalf of clients (worked extensively with japanese pharma).

  • Oncology Group Leader

    January 1995 --- January 1997

  • Clinical Scientist

    January 1990 --- January 1995


LinkedIn Assessment :
oncologyClinical trialsClinicalClinical researchCancerTherapeuticsR&DClinical DevelopmentPharmaceutical IndustryInformaticsTherapistsClinical Study DesignBiotechnologyCROMedicineDrug DevelopmentMedical affairsPharmacokineticsGCPPharmacovigilanceTherapeutic AreasMedical writingRegulatory submissionsICH-GCPTranslational Medicine


  • M.Sc in Chemistry (Analytical Toxicology & Pharmacology) from University of Greenwich in 1988
  • in from Bedford School in 1977

Area / Region

London, United Kingdom


Driving License
  • Yes

Similar Candidates

Other Candidates in United Kingdom

Other Candidates in London

Other similar Candidates in London

Other Candidates

Most Recent Searches

Most Famous Searches

You might also like